SCHEMBL3548693

SCHEMBL3548693

NC(=O)CCN1CCC(O)C1

nearest known ligand 0.52

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.52
PDCD1 Q15116 1/20 0.46
CD274 Q9NZQ7 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.40
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
HRH3 Q9Y5N1 3/20 0.36
LTA4H P09960 1/20 0.36
ALDH1A1 P00352 1/20 0.36
LMNA P02545 1/20 0.36
GAA P10253 1/20 0.36
KMT2A Q03164 1/20 0.36
DPP4 P27487 2/20 0.35
DPP7 Q9UHL4 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2673576 0.98 L3MBTL1 (0.50) L3MBTL1PDCD1CD274SMN1; SMN2POLB
SCHEMBL1006793 0.89 L3MBTL1 (0.58) L3MBTL1PDCD1CD274SMN1; SMN2POLB
SCHEMBL1007857 0.89 L3MBTL1 (0.58) L3MBTL1PDCD1CD274SMN1; SMN2POLB
SCHEMBL1008402 0.89 L3MBTL1 (0.58) L3MBTL1PDCD1CD274SMN1; SMN2POLB
SCHEMBL1008203 0.88 L3MBTL1 (0.61) L3MBTL1SMN1; SMN2POLBHTTALDH1A1
SCHEMBL1851155 0.84 L3MBTL1 (0.54) L3MBTL1PDCD1CD274SMN1; SMN2POLB
SCHEMBL13993975 0.81 PDCD1 (0.46) PDCD1CD274SMN1; SMN2POLBHTT
SCHEMBL14520291 0.81 PDCD1 (0.46) PDCD1CD274SMN1; SMN2POLBHTT
SCHEMBL1007601 0.81 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2POLBHTTALDH1A1
SCHEMBL1007110 0.81 L3MBTL1 (0.52) L3MBTL1SMN1; SMN2POLBHTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732896-B1 SUBSTITUTED PYRIDONES AS INHIBITORS OF POLY(ADP-RIBOSE) POLYMERASE (PARP) AVENTIS PHARMA INC (US) 2012-12-12 EP claimed
EP-2539345-B1 4-[CYCLOALKYLOXY(HETERO)ARYLAMINO]-THIENO[2,3-D]PYRIMIDINES HAVING MNK1/ MNK2 INHIBITING ACTIVITY FOR PHARMACEUTICAL COMPOSITIONS BOEHRINGER INGELHEIM INT (DE) 2015-07-22 EP disclosed
US-8754079-B2 Cycloalkyl containing thienopyrimidines for pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-06-17 US disclosed
US-7662824-B2 Acylhydrazones as kinase modulators JANSSEN PHARMACEUTICA NV (BE) 2010-02-16 US disclosed
US-20070066610-A1 Acylhydrazones as kinase modulators JANSSEN PHARMACEUTICAL, N.V. (BE) 2007-03-22 US disclosed
WO-2006101937-A1 ACYLHYDRAZONES AS KINASE MODULATORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066610-A1 Acylhydrazones as kinase modulators MET, ERBB2, ERBB3 L3MBTL1 1588/4885PDCD1 1804/4885CD274 2455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.